Global Dyslipidemia Market - 2024-2031

Overview

The global dyslipidemia market reached US$ 146 million in 2023 and is expected to reach US$ 219 million by 2031, growing at a CAGR of 5.6% during the forecast period 2024-2031.

Dyslipidemia is an elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high-density lipoprotein cholesterol (HDL-C) level that contributes to the development of atherosclerosis. Dyslipidemia may be primary (genetic) or secondary. Diagnosis is by measuring plasma levels of total cholesterol, TGs, and individual lipoproteins. Treatment involves dietary changes, exercise, and lipid-lowering drugs.

The primary factors driving the market are the increasing prevalence of cardiovascular diseases and dyslipidemia, advanced therapies for the treatment, and the rising geriatric population.

Market Dynamics: Drivers

Increasing Prevalence of Cardiovascular Diseases and Dyslipidemia

The demand for the global dyslipidemia market is driven by multiple factors. Dyslipidemia is one of the important contributors to cardiovascular disease and type 2 diabetes. Dyslipidemia, characterized by abnormal lipid levels in the blood, is a significant risk factor for cardiovascular diseases (CVDs) such as heart attacks and strokes. The rising burden of CVDs and the demand for dyslipidemia management and treatment are expected to drive this market growth.

In addition, the prevalence of dyslipidemia, which includes conditions like high cholesterol, high triglycerides, and low HDL cholesterol, is rising globally due to factors like obesity, sedentary lifestyles, and poor dietary habits that are driving this market growth.

According to the population medicine research publication in June 2023, the prevalence of dyslipidemia was 80.4%, 21.7% high total cholesterol (TC), 35.5% high triglycerides (TG), 20.2% high low-density lipoprotein cholesterol (LDL-C) and 68.9% low high-density lipoprotein cholesterol (HDL-C).

As per NCBI publication in July 2022, among the newly developed drugs is inclisiran, a small interfering RNA targeting hepatic PCSK9 synthesis led to increased LDL receptor recycling and potent LDL cholesterol reduction by 51% when used together with other lipid-lowering agents.

Restraints

Factors such as the high cost of R&D, stringent regulatory requirements, patent expiry of existing drugs, patient compliance issues, and lack of awareness, high cost of the newly launched drugs among individuals, are expected to hamper the market.

Segment Analysis

The global dyslipidemia market is segmented based on drug class, distribution channel, and region.

The statin drugs segment accounted for approximately 59.6% of the global dyslipidemia market share

The statin drugs segment is expected to hold the largest market share over the forecast period. Statins are currently the first line of drugs in the treatment of dyslipidemia in children and adolescents. It would reduce the risk of major vascular events by lowering low-density lipoprotein cholesterol (LDL-C).

Moreover, key players in the market more focus on the treatment of dyslipidemia, and product launches and approvals would drive this segment growth. For instance, in June 2024, Daewoong Bio launched a new product that combines hyperlipidemia drug rosuvastatin with the dietary supplement Omega-3. It offers improvements in lipids and instability and tolerability compared to rosuvastatin alone.

Also, in July 2023, Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.

Geographical Analysis

North America accounted for approximately 43.2% of the global dyslipidemia market share

North America region is expected to hold the largest market share over the forecast period. owing to the increasing prevalence of hypercholesteremia, increasing healthcare expenditure and the presence of a well-established healthcare infrastructure drive this market growth in this region.

Moreover, the rising prevalence of dyslipidemia in this region propels this market growth.

According to new data from the Strong Heart Study (SHS), in March 2024, the young American Indian population, more than 70% of young adults and more than 50% of adolescents had dyslipidemia, and some had subclinical or clinical cardiovascular disease (CVD).

Moreover, the major number of key player presence, government awareness programs, and drug launches would help this market growth. For instance, in April 2024, the Canadian Cardiovascular Society (CCS) launched a national lipid screening awareness campaign to encourage people at risk of ASCVD to get their cholesterol, triglycerides, and Lp(a) levels tested and seek support from their healthcare provider.

Also, in November 2023, at the American Heart Association (AHA) Scientific Sessions in Philadelphia, Arrowhead Pharmaceuticals launched plozarsiran and zodasiran hold the potential to treat dyslipidemia.

Market Segmentation

By Drug Class

• Statin Drugs
  • Atorvastatin
  • Lovastatin
  • Rosuvastatin
  • Others
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• Fibrates
• Niacins
• Omega-3 Fatty Acid Derivatives

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the dyslipidemia market include AstraZeneca, Merck & Co., Inc., Pfizer Inc., Sanofi, Abbott, Mylan N.V., Novartis Pharmaceuticals Corporation, Teva Pharmaceutical Industries Ltd, Lupin and Esperion Therapeutics, Inc among others.

Key Developments

• In January 2024, New Amsterdam Pharma Company N.V. developed oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated.
• In November 2023, CKD Pharm launched a reduced dosage of the dyslipidemia drug Lipilow. It was released the renewed versions of Lipilow were 20mg, 40mg, and 80mg.
• In October 2023, Zydus announced that it has received permission from CDSCO, India to initiate the Phase I clinical study of its novel PCSK9 inhibitor. It aims to treat Dyslipidemia by inhibiting PCSK9 with a novel entity.
• In October 2022, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities.
• In September 2022, Servier is launching a new edition of the "#BecauseISaySo" prevention campaign in over 40 countries. The "TakeYourMedicine" component focuses attention on the need to take blood pressure medication and, for the first time, cholesterol medication.
• In May 2022, Zydus Lifesciences launched in India its Bempedoic acid drug under the Bemdac brand for the treatment of uncontrolled levels of bad cholesterol.
• In April 2022, AstraZeneca introduced the AZD8233 reduced low-density lipoprotein cholesterol levels by 73% in patients with high-risk hypercholesterolemia in the ETESIAN Phase IIb trial.

Why Purchase the Report?

• To visualize the global dyslipidemia market segmentation based on drug class, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global dyslipidemia market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global dyslipidemia market report would provide approximately 54 tables, 49 figures, and 182 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies